✦ LIBER ✦

Vascular characterisation of triple negative breast carcinomas using dynamic MRI

✍ Scribed by Sonia P. Li; Anwar R. Padhani; N. Jane Taylor; Mark J. Beresford; Mei-Lin W. Ah-See; J. James Stirling; James A. d’Arcy; David J. Collins; Andreas Makris

Book ID: 113032842
Publisher: Springer
Year: 2011
Tongue: English
Weight: 715 KB
Volume: 21
Category: Article
ISSN: 0938-7994
DOI: 10.1007/s00330-011-2061-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

2112 Disease characterisation of triple

2112 Disease characterisation of triple negative breast carcinomas using functional MRI

✍ S. Li; A. Makris; N.J. Taylor; M.W. Ah-See; D. Wellsted; M.J. Beresford; J.J. St 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Differentiation of scar tissue and carci

Differentiation of scar tissue and carcinoma of the breast using MRI with GD-DTPA dynamic enhancement

📂 Article 📅 1992 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Inference of the Basal Epithelial Phenot

Inference of the Basal Epithelial Phenotype in Breast Carcinoma from Differential Marker Expression, Using Tissue Microarrays in Triple Negative Breast Cancer and Women Younger than 35

✍ Aziza Nassar; Zachary M Sussman; Diane Lawson; Cynthia Cohen 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 742 KB

Comparison of triple-negative and estrog

Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters : A potentially useful method for disease characterization

✍ Sandip Basu; Wengen Chen; Julia Tchou; Ayse Mavi; Tevfik Cermik; Brian Czernieck 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND. This study was designed to investigate the fluorine‐18 fluorodeoxyglucose (FDG)‐positron emission tomography (PET) imaging characteristics of triple‐negative (estrogen receptor‐negative [ER−]/progesterone receptor‐negative [PR−]/HER2‐negative [HER2−]) breast carcinoma an